MMP9 is mainly regulated at the transcriptional level; polymorphisms located in the promoter region have been associated with myocardial infarction, ischaemic stroke, coronary artery disease, lung disorders and a variety of carcinomas (i.e. gastric, breast, urinary) [11,64,66,67]. Here, MMP9 is linked to myocardial infarction.